FT : Chinese property is beyond repair. How can creditors delay its collapse?

Chinese property is beyond repair. How can creditors delay its collapse?
Patch up the roof, ignore the foundations, feed the hedgies

In 2022 we were describing China’s property crash as “a slow-motion financial crisis”. In retrospect it wasn’t all that slow-motion. The chart below is from Barclays’ 2024 Credit Outlook:

More than half of China’s top developers followed Evergrande into default after Beijing moved in 2020 to restrict new borrowing, unravelling a funding model that was built on dollar-denominated high-yield debt and bankrolled by local government financing vehicles.

Since the beginning of 2020, at least 60 China property issuers with more than $140bn in outstanding dollar bonds have defaulted, Barclays calculates:

What now? New foundations are needed for the rebuild, paid for with principal haircuts, bond issuance and debt-for-equity swaps. However, “many of the debt plans proposed by developers so far have been intended to buy time, rather than to meaningfully improve their capital structures to more sustainable levels,” says Barclays.

Too many Chinese privately owned developers remain riddled with debt and lack an equity buffer. Off-balance sheet and contingent liabilities are also common.

Liabilities across the sector stood at 87 per cent of assets at the end of June, compared with asset-to-liabilities ratios of 69 per cent for the Chinese state-owned builders and 41 per cent for the Hong Kong peer group, according to Barclays. China’s “red three lines” credit policy caps debt-to-asset ratio at 70 per cent, though it was relaxed in January.


With so little equity on the balance sheet, a further 20 per cent decline in the book value of property and plant inventories on average would be enough to cause wipeout, Barclays calculates. (Note that the sample above includes Country Garden and Evergrande, both of which were deep in negative equity at the half-year. The former defaulted in October and the latter might be liquidated next month.)

Measuring assets is another problem. The high contract liabilities seen in the chart above are because developers pre-sell property and flip the cash into the next project. The actual unsold property on their books might therefore be lower than reported, which drags both on potential recovery values in liquidation and continuing cash flow if the business can be saved.

Note also the very high levels of payables, which push bond creditors further back in the queue, and their relative lack of tangible assets. The sector is virtually designed to evaporate on the first signs of bust. Here is the consequence.

What kind of a debt haircut is needed to save a fly-by-night property developer that lacks cash flow, equipment, and property? It’s impossible to say, so “more than one” is a reasonable answer. Averting each short-term liquidity crunch won’t solve a solvency problem but it kicks the can down the road, which is probably the most that can be hoped for right now.

Back to Barclays:

Stripping out Evergrande, we estimate that an average 30% haircut of the total interest-bearing debts for the other 26 POE developers may be required to: 1) improve EBITDA coverage ratios to more than 1.5x; and 2) lower debt/EBITDA ratios to 8x or below, assuming 6% average interest costs, 15% EBITDA margin, and normalised contracted sales at the 2022 level. 

Moreover, if only offshore creditors have to bear the cost of the restructuring (ie, no haircuts on onshore debts), then we estimate the potential debt haircuts would need to increase to around 70% for offshore debts, assuming offshore debt accounts for 50% of interest-bearing debts.

The big additional complication is, well, China. In September, Chinese regulators pushed Evergrande closer to liquidation by blocking a plan to restructure offshore debt with new issuance. Can-kicking exercises by other developers is similarly beholden to Beijing, even when it works, and right now it often doesn’t.

Modern Land completed a restructuring a year ago, then last month asked to amend terms ahead of the year-end due date on its first amortised bond. Powerlong and KWG have both defaulted having agreed term extensions last year, while China South City has asked for grace three times since its 2022 restructuring.

What could go right? Barclays uses as a case study Sunac, a top-three developer whose 2021 sales were equivalent to nearly $85bn. Sunac defaulted in April 2022, beginning a 19-month restructuring process involving $10.2bn of offshore debt from which it exited last month.

Creditors voted overwhelmingly in favour of Sunac swapping debt for a clutch of equity-linked instruments that have delivered to recent buyers a quick profit. Key to the proposal was to give creditors the ability to switch back and forth between equity and debt claims, so they could gain exposure to a Chinese property recovery story as well as an easy exit.

It won’t be long before Sunac needs to kick the can again, however. There were no haircuts for onshore debt, which was approximately three-quarters of the total, so while the debt-for-equity swap nearly halved offshore debt the overall indebtedness barely changed. The refinancing also lacked any injection of fresh capital, so Sunac bought two years at most of breathing space. Everything still depends on a property market recovery.

Can other developers follow the Sunac template? It’s doubtful. The restructuring worked because Sunac had an equity buffer and its majority owner, founder and chair Sun Hongbin, was willing to be diluted. And arguably, in a sector full of Potemkin village architects, Sunac is a relatively high-quality play.

Nevertheless, the post-deal price strength of Sunac equity instruments “may have far-reaching implications for other defaulted issuers looking to work out a restructuring deal”, says Barclays.

It calculates that an investor buying the bonds in the three months before restructuring was signed off in September would be up 11 per cent. Here are Barclays’s numbers:

If other companies can follow Sunac’s example they’re inviting hedge funds into a very obvious trade: buy the bond, vote through the restructuring and slot the equity at the first opportunity. It won’t rescue anyone. It won’t even right-size any balance sheets. It certainly won’t help sell more houses.

But it might just be enough to give the can one more kick.

FT : Gas found in Zimbabwe by Australian energy group Invictus

Gas found in Zimbabwe by Australian energy group Invictus
Discovery of samples raises hopes that nation hit by power shortages could become a producer

Invictus Energy has discovered gas in Zimbabwe, raising hopes the landlocked southern African nation could become a producer decades after ExxonMobil abandoned a search for oil in the region.

The Australian-based company said four samples from a well in the north had shown the presence of gas in a country that has suffered severe power shortages and endured years of economic hardship.

Shares in Invictus surged 28 per cent to A$0.20 on Thursday — the highest daily rise in a year, although from a low base.

“The discovery represents one of the most significant developments in the onshore southern Africa oil and gas industry for decades,” said Scott Macmillan, managing director of Invictus.

Sydney-listed Invictus, which used data collected by Mobil before it merged with Exxon, will drill more wells at the Cabora Bassa project to find how much gas there is there — and production could be years away.

Viable gas for energy generation could help relieve the power shortages that have caused big disruptions for major miners operating in the country.

At present, platinum producers, including a unit of Anglo American, Chinese-backed lithium miners and gold companies have to pay to import electricity from abroad.

The tip of Africa has seen a renaissance in oil and gas exploration since Mozambique, Zimbabwe’s neighbour, discovered vast offshore gas finds more than a decade ago.

Discoveries onshore, where resources could be plugged into local industrialisation and not just exported to world markets, remain rare.

TotalEnergies and Shell are among the investors betting on deepwater oil discoveries in Namibia. South Africa is hoping to tap gas off its coast.

Zimbabwe might appear an unlikely candidate to join them given its forbidding reputation for abuse of resource wealth and political chaos that has persisted since the downfall of Robert Mugabe in a 2017 coup. 

Under Emmerson Mnangagwa, who was elevated to power by Zimbabwe’s military and was re-elected as president in a disputed vote this year, the country’s wealth in gold and diamonds remains tainted by allegations of systemic looting. Mnangagwa’s ruling Zanu-PF has been in power since independence in 1980.

“Historically, natural resource extraction in Zimbabwe has tended to only benefit a political elite, often at the expense of local communities and ordinary citizens, and failed to translate into development gains,” said Zimbabwe’s Centre for Natural Resource Governance in a report on the gas exploration project this year.

Invictus’s Macmillan said that gas by its nature was less susceptible to these risks. “Gas is a different type of resource because you need pipelines, infrastructure and long-term customers,” he said. “It’s a very different scenario from precious metals, which are fungible” and move more easily.

Zimbabwean pension funds are among the investors in Invictus and the company and the project will eventually need a production-sharing deal with the Zimbabwean state.

Mobil stopped exploring because “they thought that there was no way for them to commercialise gas, which was true in the early 1990s”, Macmillan said. Due to the power crisis, “we live in a very different environment now from a commercialisation perspective”.

“Often with gas developments, you have to wait for customers and markets. There are existing consumers [in Zimbabwe] who are paying hard cash to import electricity,” he added.

>>> Cytokinetics presents results from COURAGE-ALS at the 34th International Sy

Cytokinetics presents results from COURAGE-ALS at the 34th International Symposium on ALS/MND (33.46)
  • COURAGE-ALS was designed with two planned interim analyses of unblinded data by the Data Monitoring Committee. At the second interim analysis the Data Monitoring Committee recommended the discontinuation of the clinical trial due to futility. Subsequently, the Company concluded study conduct in March 2023 and discontinued treatment with reldesemtiv in all patients including those in the open-label extension study, COURAGE-ALS OLE. Development of reldesemtiv has been terminated.
  • At the time of the discontinuation of COURAGE-ALS, 486 patients had started treatment with reldesemtiv or placebo and 276 had completed dosing through 24 weeks. Treatment with reldesemtiv for 24 weeks had no effect on the primary efficacy endpoint measure of change from baseline up to Week 24 in the ALS Functional Rating Scale Revised (ALSFRS-R) (joint rank test p=0.11). Patients treated with reldesemtiv declined 5.3 points per month (SD=5.3) while patients treated with placebo declined 4.8 points per month (SD=4.4). No pre-defined patient subgroup favored treatment with reldesemtiv. Patients with a faster disease progression rate did not experience a greater treatment effect from reldesemtiv, contrary to analyses conducted post hoc from FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv, which had suggested that treatment effects were more evident in patients with a faster disease progression rate. Reldesemtiv also demonstrated no effect on key secondary endpoints including change from baseline to Week 24 in in-clinic percent predicted forced vital capacity (FVC), ALS Questionnaire 40 (ALSAQ-40) and handgrip strength.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • CXM -28.2%, AI -11.4%, CHWY -11.4% (also names new CFO), NAPA -9.4%, SPWH -8.8%, GME -8.8%, AGX -6.3%, GEF -6%, OXM -3.5%, CHPT -3.4%, VEEV -2.5%
Other news:
  • WVE -22.7% (prices $100 million public offering of ordinary shares)
  • NKLA -18.1% (announces $100 mln stock offering; also $200 mln convertible notes offering)
  • SEAT -13.4% (files for 18.5 mln share offering by selling shareholder)
  • HCI -5.9% (prices offering of 1.0 mln shares of common stock at $78.00 per share)
  • ETNB -5.8% (announces upsized pricing of $150.0 million public offering of common stock and pre-funded warrants)
  • CNM -4.2% (selling shareholders commence 15 mln share offering; CNM to repurchase of 3.13 mln of these shares and 1.87 mln partnership interests)
  • PYCR -3% (selling shareholder commences 5 mln share offering)
  • HIVE -2.6% (provides November production update)
  • MNOV -1.8% (receives a notice of decision to grant for a new patent covering MN-166 (ibudilast) for the treatment of progressive MS in Europe)
  • BECN -1.4% (prices secondary offering of 5 million shares of common stock)
Analyst comments:
  • DHR -1.7% (downgraded to Neutral from Buy at Goldman)
  • TTWO -1.7% (downgraded to Neutral from Buy at BofA Securities)
  • VOD -1.4% (downgraded to Underperform from Neutral at Exane BNP Paribas)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • SMTC +13.8%, VRNT +9.2%, BRZE +8.3%, JBLU +7.8% (guidance), DG +3%, CIEN +3%, BASE +1.9%
Other news:
  • ASLE +17.4% (receives Boeing 737NG Supplemental Type Certificate for its Enhanced Flight Vision System "AerAware")
  • VNDA +16.6% (acquires U.S. and Canadian rights to PONVORY (ponesimod) from Johnson & Johnson's (JNJ) Actelion Pharmaceuticals)
  • CERE +14.1% (ABBV to acquire CERE for $45/sh)
  • ANIX +4.1% (Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine)
  • AORT +3.8% (CFO retires names new CFO) CYTK +2.2% (presents results from COURAGE-ALS at the 34th International Symposium on ALS/MND)
  • FSR +2.1% (issues statement says negative reports about co have been overblown)
  • ASR +2% (reports Nov traffic)
  • FWRD +1.7% (provides mid-quarter update)
  • TRN +1.7% (increases dividend)
  • DNA +1.5% (signs MoU with Synplogen to accelerate the development of DNA manufacturing and gene therapy in Japan)
  • BHP +1.4% (CFO and executive leadership team update; Vandita Pant has been appointed Chief Financial Officer)
  • PAX +1.2% (to acquire Credit Suisse's real estate business in Brazil for ~$130 mln)
  • BMY +1.2% (increases dividend; announces additional $3 billion share repurchase authorization)
  • LEV +1.2% (announced the successful final certification for its medium duty battery pack the LionBattery MD a lithium-ion battery pack specifically designed for the Company's medium duty trucks and school buses)
  • CMPS +1.1% (study results of psilocybin published in JAMA Psychiatry)
Analyst comments:
  • VTGN +14.2% (upgraded to Buy from Hold at Jefferies)
  • BVS +5.3% (upgraded to Buy from Hold at Canaccord Genuity)
  • EQNR +2.7% (upgraded to Buy from Neutral at BofA Securities)
  • SPHR +2% (upgraded to Buy from Neutral at Seaport Research Partners)
  • DDOG +1.5% (upgraded to Buy from Hold at Stifel)
  • BIIB +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
  • SNDR +1.1% (upgraded to Equal Weight from Underweight at Wells Fargo)

>>> Europe : Brokers Upgrades & Downgrades - 7th of December 2023 V3(++)

>>> Up
* Adyen Raised to Buy at Jefferies; PT 1,396 euros
* Aiforia Technologies Raised to Accumulate at Inderes
* Deutsche Post AG Raised to Neutral at JPMorgan; PT 43.80 euros
* Epiroc Raised to Buy at DNB Markets; PT 230 kronor
* Qiagen Raised to Buy at Goldman (++)
* SEB Raised to Market Perform at KBW; PT 155 kronor
* Sika Raised to Neutral at JPMorgan; PT 237 Swiss francs
* Zug Estates Raised to Outperform at ZKB

>>> Down
* Air France-KLM Cut to Underweight at JPMorgan (+)
* Boliden Cut to Underweight at Morgan Stanley; PT 250 kronor
* BRANICKS Group AG Cut to Sell at Bankhaus Metzler; PT 3 euros (+)
* Continental Cut to Hold at HSBC; PT 75 euros
* Danaher Cut to Neutral at Goldman (++)
* IAG Cut to Underweight at JPMorgan (+)
* Kering Cut to Neutral at BNPP Exane; PT 440 euros (+)
* Kingspan Cut to Underweight at JPMorgan; PT 65 euros
* Lufthansa Cut to Underweight at JPMorgan (+)
* Petrofac Cut to Hold at SocGen; PT 26 pence
* Pierer Mobility Cut to Hold at Stifel; PT 63.66 euros
* Revenio Cut to Accumulate at Inderes; PT 25.50 euros
* Rockwool Cut to Underweight at JPMorgan; PT 1,720 kroner
* Salvatore Ferragamo Cut to Sell at Deutsche Bank; PT 11 euros
* SSAB Cut to Equal-Weight at Morgan Stanley; PT 80 kronor
* Swatch Cut to Hold at Deutsche Bank; PT 240 Swiss francs
* Telia Raised to Neutral at BNPP Exane; PT 25 kronor
* Vodafone Cut to Underperform at BNPP Exane; PT 68 pence
* Worldline Cut to Underperform at Jefferies; PT 12.30 euros
* WPP Cut to Neutral at Oddo BHF; PT 990 pence (++)

>>> Initiation
* Airbus ADRs Rated New Sell at Berenberg; PT $27
* CAF Rated New Buy at SocGen; PT 42 euros (+)
* Coca-Cola Femsa ADRs Rated New Neutral at Citi; PT $90
* CVS Group Rated New Buy at Panmure Gordon; PT 2,085 pence
* GSEO LN Rated New Neutral at Peel Hunt (+)
* Oxford Biomedica Reinstated Buy at Peel Hunt; PT 475 pence
* Vaisala Rated New Buy at Danske Bank Markets; PT 45 euros (++)

>>> Call
* Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
* Anglo, Antofagasta and Rio Tinto Citi’s Top Europe Mining Picks
* Morgan Stanley Selective in Diversifieds, Bullish on Copper
* European Telecoms Eye 2024 Cash-Flow Gains on Profit Resilience
* Goldman Strategists Say US Stocks Vulnerable to Any Macro Shock (+)
* JPMorgan Now More Cautious on Airlines, Upgrades Deutsche Post (+)
* Vodafone Falls on Exane Cut as Deals Risk Future Cash Flow (++)
* Qiagen Now a Buy at Goldman, Danaher Cut in Life Science Tools (++)

>>> Europe : Brokers Upgrades & Downgrades - 7th of December 2023 V2(+)

>>> Up
* Adyen Raised to Buy at Jefferies; PT 1,396 euros
* Aiforia Technologies Raised to Accumulate at Inderes
* Deutsche Post AG Raised to Neutral at JPMorgan; PT 43.80 euros
* Epiroc Raised to Buy at DNB Markets; PT 230 kronor
* SEB Raised to Market Perform at KBW; PT 155 kronor
* Sika Raised to Neutral at JPMorgan; PT 237 Swiss francs
* Zug Estates Raised to Outperform at ZKB

>>> Down
* Air France-KLM Cut to Underweight at JPMorgan (+)
* Boliden Cut to Underweight at Morgan Stanley; PT 250 kronor
* BRANICKS Group AG Cut to Sell at Bankhaus Metzler; PT 3 euros (+)
* Continental Cut to Hold at HSBC; PT 75 euros
* IAG Cut to Underweight at JPMorgan (+)
* Kering Cut to Neutral at BNPP Exane; PT 440 euros (+)
* Kingspan Cut to Underweight at JPMorgan; PT 65 euros
* Lufthansa Cut to Underweight at JPMorgan (+)
* Petrofac Cut to Hold at SocGen; PT 26 pence
* Pierer Mobility Cut to Hold at Stifel; PT 63.66 euros
* Revenio Cut to Accumulate at Inderes; PT 25.50 euros
* Rockwool Cut to Underweight at JPMorgan; PT 1,720 kroner
* Salvatore Ferragamo Cut to Sell at Deutsche Bank; PT 11 euros
* SSAB Cut to Equal-Weight at Morgan Stanley; PT 80 kronor
* Swatch Cut to Hold at Deutsche Bank; PT 240 Swiss francs
* Telia Raised to Neutral at BNPP Exane; PT 25 kronor
* Vodafone Cut to Underperform at BNPP Exane; PT 68 pence
* Worldline Cut to Underperform at Jefferies; PT 12.30 euros

>>> Initiation
* Airbus ADRs Rated New Sell at Berenberg; PT $27
* CAF Rated New Buy at SocGen; PT 42 euros (+)
* Coca-Cola Femsa ADRs Rated New Neutral at Citi; PT $90
* CVS Group Rated New Buy at Panmure Gordon; PT 2,085 pence
* GSEO LN Rated New Neutral at Peel Hunt (+)
* Oxford Biomedica Reinstated Buy at Peel Hunt; PT 475 pence

>>> Call
* Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
* Anglo, Antofagasta and Rio Tinto Citi’s Top Europe Mining Picks
* Morgan Stanley Selective in Diversifieds, Bullish on Copper
* European Telecoms Eye 2024 Cash-Flow Gains on Profit Resilience
* Goldman Strategists Say US Stocks Vulnerable to Any Macro Shock (+)
* JPMorgan Now More Cautious on Airlines, Upgrades Deutsche Post (+)

>>> Stoxx 600 Pre-Market Indications

  • BAT (BMT TH) +1.4%
  • Sanofi (SNW TH) +1.1%
  • Adyen (1N8 TH) +0.5%
    • Adyen Among Favored Payments Stocks at Jefferies, Worldline Cut
  • Rio Tinto (RIO1 TH) +0.3%
    • Morgan Stanley Selective in Diversifieds, Bullish on Copper
  • ING (INN1 TH) -1.3%
  • Rolls-Royce (RRU TH) -1.4%
  • Evotec SE (EVT TH) -1.4%
  • TotalEnergies (TOTB TH) -1.4%
    • Big Oil Shouldn’t Lead the Green Energy Transition: Javier Blas
  • Airbus (AIR TH) -1.4%
  • Encavis (ECV TH) -1.6%
  • Nel (D7G TH) -1.7%
  • Siemens Energy (ENR TH) -1.9%
  • Continental (CON TH) -3%
  • Lufthansa (LHA TH) -3.9%
    • Lufthansa Cut to Underweight at JPMorgan

>>> TradeGate Pre-Market Indications

DAX:
  • Infineon (IFX TH) -0.8%
    • Watch European Chipmakers as AMD Gives Eye-Popping Forecast
  • Airbus (AIR TH) -1.5%
  • Continental (CON TH) -2.3%
    • Continental Cut to Hold at HSBC; PT 75 euros
MDAX:
  • Hensoldt (HAG TH) +2.9%
  • ProSieben (PSM TH) -1%
  • Lufthansa (LHA TH) -3.6%
SDAX:
  • Metro (B4B TH) +1.1%
  • Heidelberger Druck (HDD TH) -1%
  • PVA TePla (TPE TH) -1.6%
  • Borussia Dortmund (BVB TH) -2.5%